Teachers Retirement System of The State of Kentucky Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Teachers Retirement System of The State of Kentucky lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 21,391 shares of the medical equipment provider’s stock after selling 610 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Lantheus were worth $2,347,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Coldstream Capital Management Inc. purchased a new position in shares of Lantheus during the 3rd quarter valued at $230,000. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% during the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares during the period. M&T Bank Corp lifted its position in shares of Lantheus by 40.4% in the third quarter. M&T Bank Corp now owns 6,847 shares of the medical equipment provider’s stock valued at $752,000 after acquiring an additional 1,969 shares in the last quarter. Groupama Asset Managment bought a new position in shares of Lantheus in the third quarter worth about $439,000. Finally, MML Investors Services LLC grew its position in shares of Lantheus by 24.6% during the third quarter. MML Investors Services LLC now owns 4,338 shares of the medical equipment provider’s stock worth $476,000 after purchasing an additional 857 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Truist Financial restated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $130.00.

Lantheus Stock Performance

NASDAQ LNTH opened at $93.02 on Monday. The business’s 50 day moving average price is $97.88 and its 200-day moving average price is $98.11. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a market cap of $6.47 billion, a P/E ratio of 15.48 and a beta of 0.45.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.